HPRA Drug Safety Newsletter Edition 92

Download: hpra-drug-safety-newsletter-edition-92.pdf 272 KB

 The latest edition of the HPRA Drug Safety Newsletter (DSN) includes important updates regarding the following medicines:

  • Use of Lemtrada restricted while EMA review is on-going
  • SGLT-2 inhibitors and risk of Fourniers Gangrene
  • Cobicistat boosted darunavir and elvitegravir – avoid use in pregnancy due to potential risk of virological failure in second and third trimester
  • Direct-Acting Antivirals for chronic hepatitis C – Risk of hypoglycaemia in patients with diabetes
  • Biotin – Interference with clinical laboratory tests

« Back